Abatacept

證據等級: L5

預測適應症: 10 個

ABATACEPT: Drug Repurposing Preliminary Assessment

One-Sentence Summary

Abatacept (DrugBank: DB01281) is a selective T-cell co-stimulation modulator (CTLA4-Ig fusion protein), widely used internationally for rheumatoid arthritis and other autoimmune conditions. Currently, no TxGNN predicted indications are available for evaluation, and the drug is not marketed in Taiwan. This report serves as a preliminary data inventory; further data collection is required before repurposing assessment can proceed.

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (no Taiwan licenses)
Predicted New Indication	None — TxGNN prediction not yet available
TxGNN Prediction Score	N/A
Evidence Level	L5 (Insufficient data)
Taiwan Market Status	✗ Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on publicly known information, Abatacept is a soluble fusion protein consisting of the extracellular domain of human CTLA-4 linked to the modified Fc portion of human IgG1. It functions as a selective T-cell co-stimulation modulator by binding to CD80/CD86 on antigen-presenting cells, thereby blocking the CD28 co-stimulatory signal required for full T-cell activation.

Internationally, Abatacept (brand name: Orencia®) has been approved for rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. However, these indications are not reflected in the current evidence pack as the drug holds no Taiwan FDA (TFDA) marketing authorization.

Since no TxGNN-predicted indications have been generated, it is not possible to evaluate mechanistic plausibility for any specific repurposing candidate at this time. The TxGNN model prediction pipeline should be run with Abatacept's knowledge graph data to identify potential new indications.

Clinical Trial Evidence

No predicted indication is available; therefore, no indication-specific clinical trial search was conducted.

Literature Evidence

No predicted indication is available; therefore, no indication-specific literature search was conducted.

Taiwan Market Information

Abatacept currently holds no marketing authorization from the Taiwan FDA (TFDA). There are no licensed products in Taiwan.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA package insert warnings, contraindications, and drug-drug interaction data were not retrievable for this drug (no Taiwan marketing authorization exists). Safety evaluation should reference international labelling (e.g., US FDA, EMA) if a repurposing candidate is identified.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence pack is critically incomplete — there are no TxGNN-predicted indications to evaluate, no Taiwan market authorization data, and no locally available safety labelling. Without a target indication, a repurposing assessment cannot proceed.

To proceed, the following is needed:

Run TxGNN prediction pipeline for Abatacept (DB01281) to generate candidate repurposing indications
Obtain mechanism of action (MOA) data from DrugBank API (Data Gap DG002, severity: High)
Obtain safety labelling data — either from TFDA (if future approval occurs) or from international regulatory sources such as the US FDA or EMA (Data Gap DG001, severity: Blocking)
Assess Taiwan regulatory pathway — since Abatacept is not currently marketed in Taiwan, determine whether importation or special access programs would be feasible for any identified repurposing indication
Re-evaluate once predicted indications and safety data are available
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.